Navigation Links
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
Date:1/15/2014

LAVAL, Quebec, Jan. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all of the outstanding shares of common stock of Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") at a price of $2.92 per share, net to the seller in cash, without interest (less any required withholding taxes) and subsequent merger of Purchaser with Solta expired at 11:59 p.m., New York City time on January 14, 2014.  The expiration of the HSR waiting period satisfies one of the conditions to consummate the tender offer.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-Looking Statements

This press release may contain forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Solta and expected timing of the transaction.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties.  Investors should note that many factors could affect the proposed business combination of the
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
2. Valeant Pharmaceuticals To Present At Industry Conferences
3. Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash
4. Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
6. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
7. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
8. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
9. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
10. Valeant Pharmaceuticals Announces Continuance
11. Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... BEIJING , March 27, 2015 ... the "Company") (NYSE: CCM ), a leading ... the largest network of radiotherapy and diagnostic imaging ... announced the signing of a purchase agreement under ... wholly owned subsidiary of the Company, agreed to ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... SEATTLE, May 9 The risk of the two ... be,reduced by changes in lifestyle, such as avoiding smoking, ... Kristal, Dr.P.H., associate,head of the Cancer Prevention Program at ... studies that suggest men need not,feel helpless against prostate ...
... - Fifth International Phase III Study Shows Positive Results with X-ray ... ... May 9 Roche today announced one-year,results from a new two-year Phase ... to,joints in patients with rheumatoid arthritis (RA), a critical measure of,effectiveness of ...
Cached Medicine Technology:Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 3Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5
(Date:3/28/2015)... (PRWEB) March 28, 2015 Could genetic ... a new study by researchers at the ... Produced with the support of the Coffee and Caffeine ... Molecular Psychiatry this past fall, the study—one of several ... of genomic data from more than 120,000 regular coffee ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians ... osteoarthritis and musculoskeletal diseases gathered here for the ... first time in the 17-year history of the ... topic is an emerging non-pharmaceutical protocol for enhancing ... of Wolff’s law, osteogenic loading at multiples of ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... Centurion Service Group will be hosting a live on-site ... their Las Vegas warehouse, located at 4606 Andrews St. Suite ... of equipment from hospitals and surgery centers from around the ... , Buyers will find items of all types including anesthesia, ... said Erik Tivin, CEO of Centurion. , Among the sale’s ...
(Date:3/28/2015)... How best to treat and recover from ... medicine. While diagnostic hip injections are commonly performed for ... research presented today at the American Orthopaedic Society for ... pain relief from this diagnostic injection may not predict ... study looked to assess if the amount of pain ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... prime minister Jose Socrates is smiling. His move to lift a ... voting doing so in favor of the ban being lifted or, ... and Poland- strong catholic nations that prohibit abortion or destruction of ... abort can face up to 3 years prison term and those ...
... monitored more carefully according to reports sounded at the ... a higher risk of giving birth to still-born babies, than ... Yale School of Medicine, who put forward results made after ... ,It was seen that the risk of intrauterine fetal ...
... increases a woman’s risk of becoming infected with HIV, ... edition of The Journal of Infectious Diseases (now online). ... sexually transmitted infections increase the risk of transmission and ... of Trichomonas vaginalis per year worldwide, there are few ...
... alloy surfaces containing at least 90 per cent copper completely ... of the pathogen-killing// properties of the metal. ,The ... on the mix of metals they use to coat the ... better means of eliminating E coli contamination in their products. ...
... The South African AIDS Vaccine Initiative (SAAVI) and the HIV ... of a Phase IIb study utilizing// Merck’s adenovirus trivalent (Ad5 ... and women over a year, and expect the study to ... (HVTN 502) began enrolling in North and South America, the ...
... Researchers at Cold Spring Harbor Laboratory (CSHL) have solved ... critical tumor suppressor gene, but have revealed// a master ... targeted and effective cancer therapy in the future," said ... by Mills, was published in the February issue of ...
Cached Medicine News:Health News:Vaginalis Increases the Risk of Becoming Infected With HIV 2Health News:Vaginalis Increases the Risk of Becoming Infected With HIV 3Health News:Copper Alloys Surfaces Touted As Pathogen Killers 2Health News:Largest Ever African HIV Vaccine Trial Opens in South Africa 2Health News:Scientists Discover New Gene 2
... Clinical is an open platform for clinical diagnostic ... deck sizes of 75, 100, 150 and ... for your laboratory space and throughput requirements. Tecan ... to allow new applications and to evolve the ...
... maximum productivity, and proven reliability, Sorvall ... fully automatic cell washing and centrifugation ... 80-second wash cycle for stat testing, ... and standardized, reproducible procedures. High reliability, ...
Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....
... model centrifuge. High throughput, refrigeration maintains ... with all windshield rotors, lifetime reproducibility, ... a remote personal computer or laboratory ... imbalance detection and shut down, armor ...
Medicine Products: